249 related articles for article (PubMed ID: 32186930)
1. Gray Areas in the Gray Matter:
van den Bent MJ; Mellinghoff IK; Bindra RS
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-8. PubMed ID: 32186930
[TBL] [Abstract][Full Text] [Related]
2. Targeting IDH-Mutant Glioma.
Miller JJ
Neurotherapeutics; 2022 Oct; 19(6):1724-1732. PubMed ID: 35476295
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
4. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
5. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
6. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
7. Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R; de la Fuente MI
Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
11. [Precision Medicine for IDH-mutant Diffuse Glioma(Lower-grade Glioma)].
Mukasa A
No Shinkei Geka; 2022 Jan; 50(1):8-18. PubMed ID: 35169082
[TBL] [Abstract][Full Text] [Related]
12. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
13. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Gupta R; Webb-Myers R; Flanagan S; Buckland ME
J Clin Pathol; 2011 Oct; 64(10):835-44. PubMed ID: 21752797
[TBL] [Abstract][Full Text] [Related]
15. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Lodi R; Brandes AA
Mol Diagn Ther; 2021 Jul; 25(4):457-473. PubMed ID: 34095989
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Friedrich M; Bunse L; Wick W; Platten M
Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
[TBL] [Abstract][Full Text] [Related]
17. Treatment and outcomes of IDH1-mutant gliomas in elderly patients.
Giantini-Larsen AM; Abou-Mrad Z; Yu KK; Reiner AS; Bale TA; Tabar V; Bander ED
J Neurosurg; 2024 Feb; 140(2):367-376. PubMed ID: 37877960
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
19. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
20. Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.
Zhang CB; Bao ZS; Wang HJ; Yan W; Liu YW; Li MY; Zhang W; Chen L; Jiang T
J Cancer Res Clin Oncol; 2014 Jan; 140(1):45-51. PubMed ID: 24149775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]